Figure 4.(A) Subgroup analysis of SABDs. (HRs were adjusted for age, sex, income level, comorbidities, exacerbation frequency of COPD, exacerbation frequency of HF, Charlson Comorbidity Index, urbanization level and medications; medications were analyzed as time-dependent covariates, time period: 3 months). (B) Subgroup analysis of LABAs alone. (C) Subgroup analysis of ICSs alone.
() Subgroup analysis of ICS/LABA combinations. (E) Subgroup analysis of LAMA. (F) Subgroup analysis of ACEIs.
() Subgroup analysis of ARBs. (H) Subgroup analysis of cardioselective β blockers. (I) Subgroup analysis of non-selective β blockers.
() Subgroup analysis of loop diuretics. (K) Subgroup analysis of aldosterone antagonists. (L) Subgroup analysis of digoxins.
() Subgroup analysis of statin.
